Skip to main content
Erschienen in: Endocrine 2/2022

07.10.2021 | Original Article

Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥75 years old)

verfasst von: Jiaxin Yu, Xiaokun Liu, Shuohua Chen, Yan Liu, HongMin Liu, Hongwei Zheng, Ning Yang, Shouling Wu, Yuming Li

Erschienen in: Endocrine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although increased low-density lipoprotein cholesterol (LDL-C) is one of the major risk factors for the cardiovascular disease (CVD), the associations of LDL-C with CVD and all-cause mortality are unclear in elderly (≥75 years) individuals.

Methods

A total of 3674 individuals aged 75 or older underwent medical examinations at the Kailuan Group from 2006 to 2007, including 3478 males (94.67%) and 196 females (5.33%). Participants were divided into three groups based on the LDL-C level: the ideal level (LDL-C < 100 mg/dl), appropriate level (100 mg/dl ≤ LDL-C < 130 mg/dl) and elevated level (LDL-C ≥ 130 mg/dl) groups. CVD and all-cause mortality events were recorded during the follow-up period. The Cox proportional hazards regression model was applied to evaluate the effects of LDL-C on CVD and all-cause mortality events.

Results

The average follow-up time was 9.87 ± 3.60 years. After adjustment for confounding factors, the multivariate Cox proportional hazards regression model showed that the CVD risk in the elevated level group was 1.45 (95% CI, 1.08–1.95), acute myocardial infarction risk was 1.96 (95% CI, 1.19–3.24) and all-cause mortality risk was 1.18 (95% CI, 1.02–1.37) compared with those in the ideal level group. For every standard deviation increase in LDL-C levels, the CVD risk increased by 10%, acute myocardial infarction risk increased by 21% and all-cause mortality event risk increased by 4%. No association was observed between elevated LDL-C levels and the risk of stroke.

Conclusions

In the sample of older Chinese individuals investigated in the present study, elevated LDL-C levels (≥130 mg/dl) are a risk factor for CVD and all-cause mortality.
Literatur
1.
Zurück zum Zitat M. Zhou, H. Wang, X. Zeng, P. Yin, J. Zhu, W. Chen, X. Li, L. Wang, L. Wang, Y. Liu, J. Liu, M. Zhang, J. Qi, S. Yu, A. Afshin, E. Gakidou, S. Glenn, V.S. Krish, M.K. Miller-Petrie, W.C. Mountjoy-Venning, E.C. Mullany, S.B. Redford, H. Liu, M. Naghavi, S.I. Hay, L. Wang, C.J.L. Murray, X. Liang, Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 394, 1145–1158 (2019)CrossRef M. Zhou, H. Wang, X. Zeng, P. Yin, J. Zhu, W. Chen, X. Li, L. Wang, L. Wang, Y. Liu, J. Liu, M. Zhang, J. Qi, S. Yu, A. Afshin, E. Gakidou, S. Glenn, V.S. Krish, M.K. Miller-Petrie, W.C. Mountjoy-Venning, E.C. Mullany, S.B. Redford, H. Liu, M. Naghavi, S.I. Hay, L. Wang, C.J.L. Murray, X. Liang, Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 394, 1145–1158 (2019)CrossRef
2.
Zurück zum Zitat T.A. Jacobson, M.K. Ito, K.C. Maki, C.E. Orringer, H.E. Bays, P.H. Jones, J.M. McKenney, S.M. Grundy, E.A. Gill, R.A. Wild, D.P. Wilson, W.V. Brown, National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J. Clin. Lipidol. 9, 129–169 (2015)CrossRef T.A. Jacobson, M.K. Ito, K.C. Maki, C.E. Orringer, H.E. Bays, P.H. Jones, J.M. McKenney, S.M. Grundy, E.A. Gill, R.A. Wild, D.P. Wilson, W.V. Brown, National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J. Clin. Lipidol. 9, 129–169 (2015)CrossRef
3.
Zurück zum Zitat B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watts, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. van de Sluis, M.R. Taskinen, L. Tokgözoglu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38, 2459–2472 (2017)CrossRef B.A. Ference, H.N. Ginsberg, I. Graham, K.K. Ray, C.J. Packard, E. Bruckert, R.A. Hegele, R.M. Krauss, F.J. Raal, H. Schunkert, G.F. Watts, J. Borén, S. Fazio, J.D. Horton, L. Masana, S.J. Nicholls, B.G. Nordestgaard, B. van de Sluis, M.R. Taskinen, L. Tokgözoglu, U. Landmesser, U. Laufs, O. Wiklund, J.K. Stock, M.J. Chapman, A.L. Catapano, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 38, 2459–2472 (2017)CrossRef
4.
Zurück zum Zitat J. Fulcher, R. O’Connell, M. Voysey, J. Emberson, L. Blackwell, B. Mihaylova, J. Simes, R. Collins, A. Kirby, H. Colhoun, E. Braunwald, J. La Rosa, T.R. Pedersen, A. Tonkin, B. Davis, P. Sleight, M.G. Franzosi, C. Baigent, A. Keech, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397–1405 (2015)CrossRef J. Fulcher, R. O’Connell, M. Voysey, J. Emberson, L. Blackwell, B. Mihaylova, J. Simes, R. Collins, A. Kirby, H. Colhoun, E. Braunwald, J. La Rosa, T.R. Pedersen, A. Tonkin, B. Davis, P. Sleight, M.G. Franzosi, C. Baigent, A. Keech, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397–1405 (2015)CrossRef
5.
Zurück zum Zitat J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, R.G. Westendorp, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002)CrossRef J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, R.G. Westendorp, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002)CrossRef
6.
Zurück zum Zitat S. Chatterji, J. Byles, D. Cutler, T. Seeman, E. Verdes, Health, functioning, and disability in older adults-present status and future implications. Lancet 385, 563–575 (2015)CrossRef S. Chatterji, J. Byles, D. Cutler, T. Seeman, E. Verdes, Health, functioning, and disability in older adults-present status and future implications. Lancet 385, 563–575 (2015)CrossRef
7.
Zurück zum Zitat S.E. Vollset, E. Goren, C.W. Yuan, J. Cao, A.E. Smith, T. Hsiao, C. Bisignano, G.S. Azhar, E. Castro, J. Chalek, A.J. Dolgert, T. Frank, K. Fukutaki, S.I. Hay, R. Lozano, A.H. Mokdad, V. Nandakumar, M. Pierce, M. Pletcher, T. Robalik, K.M. Steuben, H.Y. Wunrow, B.S. Zlavog, C.J.L. Murray, Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study. Lancet 396, 1285–1306 (2020)CrossRef S.E. Vollset, E. Goren, C.W. Yuan, J. Cao, A.E. Smith, T. Hsiao, C. Bisignano, G.S. Azhar, E. Castro, J. Chalek, A.J. Dolgert, T. Frank, K. Fukutaki, S.I. Hay, R. Lozano, A.H. Mokdad, V. Nandakumar, M. Pierce, M. Pletcher, T. Robalik, K.M. Steuben, H.Y. Wunrow, B.S. Zlavog, C.J.L. Murray, Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the global burden of disease study. Lancet 396, 1285–1306 (2020)CrossRef
8.
Zurück zum Zitat D. Zhao, J. Liu, M. Wang, X. Zhang, M. Zhou, Epidemiology of cardiovascular disease in China: current features and implications. Nat. Rev. Cardiol. 16, 203–212 (2019)CrossRef D. Zhao, J. Liu, M. Wang, X. Zhang, M. Zhou, Epidemiology of cardiovascular disease in China: current features and implications. Nat. Rev. Cardiol. 16, 203–212 (2019)CrossRef
9.
Zurück zum Zitat S. Wu, Z. Huang, X. Yang, Y. Zhou, A. Wang, L. Chen, H. Zhao, C. Ruan, Y. Wu, A. Xin, K. Li, C. Jin, J. Cai, Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ. Cardiovasc. Qual. Outcomes 5, 487–493 (2012)CrossRef S. Wu, Z. Huang, X. Yang, Y. Zhou, A. Wang, L. Chen, H. Zhao, C. Ruan, Y. Wu, A. Xin, K. Li, C. Jin, J. Cai, Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ. Cardiovasc. Qual. Outcomes 5, 487–493 (2012)CrossRef
10.
Zurück zum Zitat Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults, 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 44, 833–853 (2016) Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults, 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 44, 833–853 (2016)
11.
Zurück zum Zitat S.M. Grundy, N.J. Stone, A.L. Bailey, C. Beam, K.K. Birtcher, R.S. Blumenthal, L.T. Braun, S. de Ferranti, J. Faiella-Tommasino, D.E. Forman, R. Goldberg, P.A. Heidenreich, M.A. Hlatky, D.W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C.E. Ndumele, C.E. Orringer, C.A. Peralta, J.J. Saseen, S.C. Smith Jr., L. Sperling, S.S. Virani, J. Yeboah, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 73, e285–e350 (2018)CrossRef S.M. Grundy, N.J. Stone, A.L. Bailey, C. Beam, K.K. Birtcher, R.S. Blumenthal, L.T. Braun, S. de Ferranti, J. Faiella-Tommasino, D.E. Forman, R. Goldberg, P.A. Heidenreich, M.A. Hlatky, D.W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C.E. Ndumele, C.E. Orringer, C.A. Peralta, J.J. Saseen, S.C. Smith Jr., L. Sperling, S.S. Virani, J. Yeboah, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 73, e285–e350 (2018)CrossRef
12.
Zurück zum Zitat S.M. Abdullah, L.F. Defina, D. Leonard, C.E. Barlow, N.B. Radford, B.L. Willis, A. Rohatgi, D.K. McGuire, J.A. de Lemos, S.M. Grundy, J.D. Berry, A. Khera, Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation 138, 2315–2325 (2018)CrossRef S.M. Abdullah, L.F. Defina, D. Leonard, C.E. Barlow, N.B. Radford, B.L. Willis, A. Rohatgi, D.K. McGuire, J.A. de Lemos, S.M. Grundy, J.D. Berry, A. Khera, Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation 138, 2315–2325 (2018)CrossRef
13.
Zurück zum Zitat M.G. Nanna, A.M. Navar, D. Wojdyla, E.D. Peterson, The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: results from the National institutes of health pooled cohorts. J. Am. Geriatr. Soc. 67, 2560–2567 (2019)CrossRef M.G. Nanna, A.M. Navar, D. Wojdyla, E.D. Peterson, The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: results from the National institutes of health pooled cohorts. J. Am. Geriatr. Soc. 67, 2560–2567 (2019)CrossRef
14.
Zurück zum Zitat M.B. Mortensen, B.G. Nordestgaard, Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396, 1644–1652 (2020)CrossRef M.B. Mortensen, B.G. Nordestgaard, Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 396, 1644–1652 (2020)CrossRef
15.
Zurück zum Zitat S.H. Kim, K.Y. Son, Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean Nationwide longitudinal study. Lipids Health Dis. 20, 3 (2021)CrossRef S.H. Kim, K.Y. Son, Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean Nationwide longitudinal study. Lipids Health Dis. 20, 3 (2021)CrossRef
16.
Zurück zum Zitat G. Nilsson, J. Ohrvik, I. Lönnberg, P. Hedberg, Ten-year survival in 75-year-old men and women: predictive ability of total cholesterol, HDL-C, and LDL-C. Curr. Gerontol. Geriatr. Res. 2009, 158425 (2009)CrossRef G. Nilsson, J. Ohrvik, I. Lönnberg, P. Hedberg, Ten-year survival in 75-year-old men and women: predictive ability of total cholesterol, HDL-C, and LDL-C. Curr. Gerontol. Geriatr. Res. 2009, 158425 (2009)CrossRef
17.
Zurück zum Zitat Y. Liang, D.L. Vetrano, C. Qiu, Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study. BMC Geriatr. 17, 294 (2017)CrossRef Y. Liang, D.L. Vetrano, C. Qiu, Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study. BMC Geriatr. 17, 294 (2017)CrossRef
18.
Zurück zum Zitat L. Bathum, R. Depont Christensen, L. Engers Pedersen, P. Lyngsie Pedersen, J. Larsen, J. Nexøe, Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. Scand. J. Prim. Health Care 31, 172–180 (2013)CrossRef L. Bathum, R. Depont Christensen, L. Engers Pedersen, P. Lyngsie Pedersen, J. Larsen, J. Nexøe, Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. Scand. J. Prim. Health Care 31, 172–180 (2013)CrossRef
19.
Zurück zum Zitat B. Gencer, N.A. Marston, K. Im, C.P. Cannon, P. Sever, A. Keech, E. Braunwald, R.P. Giugliano, M.S. Sabatine, Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396, 1637–1643 (2020)CrossRef B. Gencer, N.A. Marston, K. Im, C.P. Cannon, P. Sever, A. Keech, E. Braunwald, R.P. Giugliano, M.S. Sabatine, Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 396, 1637–1643 (2020)CrossRef
20.
Zurück zum Zitat R.G. Bach, C.P. Cannon, R.P. Giugliano, J.A. White, Y. Lokhnygina, E.A. Bohula, R.M. Califf, E. Braunwald, M.A. Blazing, Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 4, 846–854 (2019)CrossRef R.G. Bach, C.P. Cannon, R.P. Giugliano, J.A. White, Y. Lokhnygina, E.A. Bohula, R.M. Califf, E. Braunwald, M.A. Blazing, Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 4, 846–854 (2019)CrossRef
21.
Zurück zum Zitat Y. Ouchi, J. Sasaki, H. Arai, K. Yokote, K. Harada, Y. Katayama, T. Urabe, Y. Uchida, M. Hayashi, N. Yokota, H. Nishida, T. Otonari, T. Arai, I. Sakuma, K. Sakabe, M. Yamamoto, T. Kobayashi, S. Oikawa, S. Yamashita, H. Rakugi, T. Imai, S. Tanaka, Y. Ohashi, M. Kuwabara, H. Ito, Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140, 992–1003 (2019)CrossRef Y. Ouchi, J. Sasaki, H. Arai, K. Yokote, K. Harada, Y. Katayama, T. Urabe, Y. Uchida, M. Hayashi, N. Yokota, H. Nishida, T. Otonari, T. Arai, I. Sakuma, K. Sakabe, M. Yamamoto, T. Kobayashi, S. Oikawa, S. Yamashita, H. Rakugi, T. Imai, S. Tanaka, Y. Ohashi, M. Kuwabara, H. Ito, Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140, 992–1003 (2019)CrossRef
22.
Zurück zum Zitat P.R. Sinnaeve, G.G. Schwartz, D.M. Wojdyla, M. Alings, D.L. Bhatt, V.A. Bittner, C.E. Chiang, R.M.C. Flores, R. Diaz, M. Dorobantu, S.G. Goodman, J.W. Jukema, Y.U. Kim, R. Pordy, M.T. Roe, R.G. Sy, M. Szarek, H.D. White, A.M. Zeiher, P.G. Steg, Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur. Heart J. 41, 2248–2258 (2020)CrossRef P.R. Sinnaeve, G.G. Schwartz, D.M. Wojdyla, M. Alings, D.L. Bhatt, V.A. Bittner, C.E. Chiang, R.M.C. Flores, R. Diaz, M. Dorobantu, S.G. Goodman, J.W. Jukema, Y.U. Kim, R. Pordy, M.T. Roe, R.G. Sy, M. Szarek, H.D. White, A.M. Zeiher, P.G. Steg, Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur. Heart J. 41, 2248–2258 (2020)CrossRef
23.
Zurück zum Zitat P. Amarenco, J.S. Kim, J. Labreuche, H. Charles, J. Abtan, Y. Béjot, L. Cabrejo, J.K. Cha, G. Ducrocq, M. Giroud, C. Guidoux, C. Hobeanu, Y.J. Kim, B. Lapergue, P.C. Lavallée, B.C. Lee, K.B. Lee, D. Leys, M.H. Mahagne, E. Meseguer, N. Nighoghossian, F. Pico, Y. Samson, I. Sibon, P.G. Steg, S.M. Sung, P.J. Touboul, E. Touzé, O. Varenne, É. Vicaut, N. Yelles, E. Bruckert, A comparison of two LDL cholesterol targets after ischemic stroke. N. Engl. J. Med. 382, 9 (2020)CrossRef P. Amarenco, J.S. Kim, J. Labreuche, H. Charles, J. Abtan, Y. Béjot, L. Cabrejo, J.K. Cha, G. Ducrocq, M. Giroud, C. Guidoux, C. Hobeanu, Y.J. Kim, B. Lapergue, P.C. Lavallée, B.C. Lee, K.B. Lee, D. Leys, M.H. Mahagne, E. Meseguer, N. Nighoghossian, F. Pico, Y. Samson, I. Sibon, P.G. Steg, S.M. Sung, P.J. Touboul, E. Touzé, O. Varenne, É. Vicaut, N. Yelles, E. Bruckert, A comparison of two LDL cholesterol targets after ischemic stroke. N. Engl. J. Med. 382, 9 (2020)CrossRef
24.
Zurück zum Zitat P. Sever, I. Gouni-Berthold, A. Keech, R. Giugliano, T.R. Pedersen, K. Im, H. Wang, B. Knusel, M.S. Sabatine, M.L. O’Donoghue, LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial. Eur. J. Prev. Cardiol. (2020). https://doi.org/10.1177/2047487320902750 P. Sever, I. Gouni-Berthold, A. Keech, R. Giugliano, T.R. Pedersen, K. Im, H. Wang, B. Knusel, M.S. Sabatine, M.L. O’Donoghue, LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial. Eur. J. Prev. Cardiol. (2020). https://​doi.​org/​10.​1177/​2047487320902750​
25.
Zurück zum Zitat M. Bertolotti, G. Lancellotti, C. Mussi, Management of high cholesterol levels in older people. Geriatr. Gerontol. Int. 19, 375–383 (2019)CrossRef M. Bertolotti, G. Lancellotti, C. Mussi, Management of high cholesterol levels in older people. Geriatr. Gerontol. Int. 19, 375–383 (2019)CrossRef
26.
Zurück zum Zitat T.E. Strandberg, L. Kolehmainen, A. Vuorio, Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 312, 1136–1144 (2014)CrossRef T.E. Strandberg, L. Kolehmainen, A. Vuorio, Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 312, 1136–1144 (2014)CrossRef
27.
Zurück zum Zitat F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020)CrossRef F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020)CrossRef
28.
Zurück zum Zitat A.R. Orkaby, J.A. Driver, Y.L. Ho, B. Lu, L. Costa, J. Honerlaw, A. Galloway, J.L. Vassy, D.E. Forman, J.M. Gaziano, D.R. Gagnon, P.W.F. Wilson, K. Cho, L. Djousse, Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324, 68–78 (2020)CrossRef A.R. Orkaby, J.A. Driver, Y.L. Ho, B. Lu, L. Costa, J. Honerlaw, A. Galloway, J.L. Vassy, D.E. Forman, J.M. Gaziano, D.R. Gagnon, P.W.F. Wilson, K. Cho, L. Djousse, Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA 324, 68–78 (2020)CrossRef
Metadaten
Titel
Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥75 years old)
verfasst von
Jiaxin Yu
Xiaokun Liu
Shuohua Chen
Yan Liu
HongMin Liu
Hongwei Zheng
Ning Yang
Shouling Wu
Yuming Li
Publikationsdatum
07.10.2021
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02870-3

Weitere Artikel der Ausgabe 2/2022

Endocrine 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.